Pharmacoeconomic Guidelines: El Salvador
Country/Region: El Salvador
Submission Guidelines
Submission Guidelines Source:
Additional Information:
Downloadable
Templates ANNEX No.1: REQUEST FOR INCLUSION OF MEDICATIONS IN THE INSTITUTIONAL
LIST |
Information current as of Wednesday, January 31, 2024
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | Submission Guidelines |
| Title and year of the document | Technical guidelines for health technology evaluations |
| Affiliation of authors | Francisco Alabi (Minister of Health), Carlos Albarenga (Viceminister of Health), and Karla Diaz (Viceministry of Health Operations) |
| Purpose of the document | To establish the provisions for the evaluation of health technologies aimed at the inclusion, modification and exclusion of health technologies to the Institutional List of Medicines Essentials (LIME) and catalogs managed by the Directorate of Health Technologies (DIRTECS) |
| Standard reporting format included | Yes (Annex) |
| Disclosure | Not stated. |
| Target audience of funding/ author's interests | Healthcare professionals within Ministry of Health involved in the inclusion of new healthcare technologies. |
| Perspective | Public Healthcare System Perspective. |
| Indication | Yes |
| Target population | Yes |
| Subgroup analysis | Not defined. |
| Choice of comparator | Other therapies for the same indication. |
| Time horizon | 1 year (Budget Impact). |
| Assumptions required | Not defined. |
| Preferred analytical technique | Not defined. |
| Costs to be included | Cost per unit, cost per day, and cost per treatment. |
| Source of costs | Not defined. |
| Modeling | Not defined. |
| Systematic review of evidences | Systematic reviews and meta-analysis preferred as evidence, but not limited to them. |
| Preference for effectiveness over efficacy | Not defined. |
| Preferred outcome measure | Not defined. |
| Preferred method to derive utility | Not defined. |
| Equity issues stated | No. |
| Discounting costs | Not defined. |
| Discounting outcomes | No. |
| Sensitivity analysis-parameters and range | Not defined. |
| Sensitivity analysis-methods | Not defined. |
| Presenting results | Free text. |
| Incremental analysis | No. |
| Total costs vs effectiveness (cost/effectiveness ratio) | No. |
| Portability of results (Generalizability) | Not defined. |
| Financial impact analysis | Basic budget impact based on cost-per-patient and number of patients to be treated. |
| Mandatory or recommended or voluntary | Mandatory. |
Acknowledgement:
| Fernando Bonilla Sinibaldi, MD, MBA, MSc, Health Economist/Chief Consultant, Health Transformers 360, Guatemala |